Literature DB >> 25996997

Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges.

Rebecca J Grant-Klein1, Louis A Altamura, Catherine V Badger, Callie E Bounds, Nicole M Van Deusen, Steven A Kwilas, Hong A Vu, Kelly L Warfield, Jay W Hooper, Drew Hannaman, Lesley C Dupuy, Connie S Schmaljohn.   

Abstract

Cynomolgus macaques were vaccinated by intramuscular electroporation with DNA plasmids expressing codon-optimized glycoprotein (GP) genes of Ebola virus (EBOV) or Marburg virus (MARV) or a combination of codon-optimized GP DNA vaccines for EBOV, MARV, Sudan virus and Ravn virus. When measured by ELISA, the individual vaccines elicited slightly higher IgG responses to EBOV or MARV than did the combination vaccines. No significant differences in immune responses of macaques given the individual or combination vaccines were measured by pseudovirion neutralization or IFN-γ ELISpot assays. Both the MARV and mixed vaccines were able to protect macaques from lethal MARV challenge (5/6 vs. 6/6). In contrast, a greater proportion of macaques vaccinated with the EBOV vaccine survived lethal EBOV challenge in comparison to those that received the mixed vaccine (5/6 vs. 1/6). EBOV challenge survivors had significantly higher pre-challenge neutralizing antibody titers than those that succumbed.

Entities:  

Keywords:  DNA vaccine; codon-optimized; ebola virus; electroporation; filovirus; marburg virus

Mesh:

Substances:

Year:  2015        PMID: 25996997      PMCID: PMC4635690          DOI: 10.1080/21645515.2015.1039757

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  49 in total

1.  Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.

Authors:  Paul W H I Parren; Tom W Geisbert; Toshiaki Maruyama; Peter B Jahrling; Dennis R Burton
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  DNA vaccines for HFRS: laboratory and clinical studies.

Authors:  Connie S Schmaljohn; Kristin W Spik; Jay W Hooper
Journal:  Virus Res       Date:  2013-12-24       Impact factor: 3.303

3.  Processing of the Ebola virus glycoprotein by the proprotein convertase furin.

Authors:  V E Volchkov; H Feldmann; V A Volchkova; H D Klenk
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

4.  Development of a preventive vaccine for Ebola virus infection in primates.

Authors:  N J Sullivan; A Sanchez; P E Rollin; Z Y Yang; G J Nabel
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

5.  Fruit bats as reservoirs of Ebola virus.

Authors:  Eric M Leroy; Brice Kumulungui; Xavier Pourrut; Pierre Rouquet; Alexandre Hassanin; Philippe Yaba; André Délicat; Janusz T Paweska; Jean-Paul Gonzalez; Robert Swanepoel
Journal:  Nature       Date:  2005-12-01       Impact factor: 49.962

6.  Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques.

Authors:  Gene Garrard Olinger; James Pettitt; Do Kim; Cara Working; Ognian Bohorov; Barry Bratcher; Ernie Hiatt; Steven D Hume; Ashley K Johnson; Josh Morton; Michael Pauly; Kevin J Whaley; Calli M Lear; Julia E Biggins; Corinne Scully; Lisa Hensley; Larry Zeitlin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-15       Impact factor: 11.205

7.  A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS).

Authors:  Jay W Hooper; Matthew Josleyn; John Ballantyne; Rebecca Brocato
Journal:  Vaccine       Date:  2013-07-24       Impact factor: 3.641

8.  Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus.

Authors:  Gopi S Mohan; Wenfang Li; Ling Ye; Richard W Compans; Chinglai Yang
Journal:  PLoS Pathog       Date:  2012-12-13       Impact factor: 6.823

9.  Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms.

Authors:  Devon J Shedlock; Michael A Bailey; Paul M Popernack; James M Cunningham; Dennis R Burton; Nancy J Sullivan
Journal:  Virology       Date:  2010-03-20       Impact factor: 3.616

10.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger
Journal:  Nature       Date:  2014-08-29       Impact factor: 49.962

View more
  22 in total

1.  DNA vaccines 2014 meeting: Highlights and overview.

Authors:  Kenneth E Ugen; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Animal Models of Ebolavirus Infection.

Authors:  Marisa C St Claire; Dan R Ragland; Laura Bollinger; Peter B Jahrling
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

Review 3.  Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.

Authors:  John J Suschak; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2019-10-07       Impact factor: 3.452

4.  Innate Molecular and Cellular Signature in the Skin Preceding Long-Lasting T Cell Responses after Electroporated DNA Vaccination.

Authors:  Lucille Adam; Nicolas Tchitchek; Biliana Todorova; Pierre Rosenbaum; Candie Joly; Candice Poux; Catherine Chapon; Anna-Lena Spetz; Mart Ustav; Roger Le Grand; Frédéric Martinon
Journal:  J Immunol       Date:  2020-05-08       Impact factor: 5.422

Review 5.  Ebola virus vaccines - reality or fiction?

Authors:  Chad E Mire; Thomas W Geisbert; Heinz Feldmann; Andrea Marzi
Journal:  Expert Rev Vaccines       Date:  2016-05-09       Impact factor: 5.217

6.  Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.

Authors:  Callie E Bounds; Steven A Kwilas; Ana I Kuehne; Jennifer M Brannan; Russell R Bakken; John M Dye; Jay W Hooper; Lesley C Dupuy; Barry Ellefsen; Drew Hannaman; Hua Wu; Jin-an Jiao; Eddie J Sullivan; Connie S Schmaljohn
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

7.  Integrated sequence and immunology filovirus database at Los Alamos.

Authors:  Karina Yusim; Hyejin Yoon; Brian Foley; Shihai Feng; Jennifer Macke; Mira Dimitrijevic; Werner Abfalterer; James Szinger; Will Fischer; Carla Kuiken; Bette Korber
Journal:  Database (Oxford)       Date:  2016-04-21       Impact factor: 3.451

8.  Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity.

Authors:  Karen A O Martins; Christopher L Cooper; Sabrina M Stronsky; Sarah L W Norris; Steven A Kwilas; Jesse T Steffens; Jacqueline G Benko; Sean A van Tongeren; Sina Bavari
Journal:  EBioMedicine       Date:  2015-11-27       Impact factor: 8.143

9.  DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs.

Authors:  Kathleen A Cashman; Eric R Wilkinson; Suzanne E Wollen; Joshua D Shamblin; Justine M Zelko; Jeremy J Bearss; Xiankun Zeng; Kate E Broderick; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2017-11-14       Impact factor: 3.452

Review 10.  Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity.

Authors:  John J Suschak; James A Williams; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.